Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT known ✓ | P43490 | 1/20 | 0.32 |
| ▸ | ANPEP | P15144 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.41 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.38 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.38 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.38 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.38 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.37 |
| ▸ | ACSL1 | P33121 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1710560 | 1.00 | ANPEP (0.41) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL322740 | 0.96 | ANPEP (0.43) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL322739 | 0.96 | ANPEP (0.43) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| Potassium SCHEMBL607194 | 0.94 | ANPEP (0.42) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL607192 | 0.94 | ANPEP (0.42) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL15859443 | 0.82 | SLC6A12 (0.37) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL606928 | 0.82 | SLC6A12 (0.37) | ANPEPENPEPSLC6A1GABRA5GABRB2 | |
| SCHEMBL337453 | 0.78 | BRD4 (0.43) | GRM1ALDH1A1DAOKCNQ3KCNQ2 | |
| SCHEMBL337044 | 0.78 | GRM1 (0.38) | ANPEPENPEPGRM1POLBTDP1 | |
| SCHEMBL10086748 | 0.78 | BRD4 (0.43) | GRM1ALDH1A1DAOKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344482-B1 | BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | HOFFMANN LA ROCHE (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-7939535-B2 | Benzo[D]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine D3 receptors | HOFFMAN-LA ROCHE INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-20100075985-A1 | BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075985-A1 | BENZO[D]ISOXAZOL-3-YL-PIPERAZIN DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, DRD2, DRD1 | NAMPT 3661/4885ANPEP 3481/4885ENPEP 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.